GoldenGolden
Advanced Search
EpiVax (company)

EpiVax (company)

A computational immunology and vaccine development company based in Providence, Rhode Island. It was founded in 1998.

EpiVax is a Rhode Island-based immunology company dedicated to applying its tools (in-silico, in-vitro, and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines.The company has various offerings, such as vaccine services, immunogenicity assessment, deimmunizaiton, laboratory services, and pipeline services.

COVID-19

The company has been developing a peptide-based, epitope-driven vaccine candidate for healthcare workers who are working during the COVID-19 pandemic. It has partnered with the GAIA Vaccine Foundation (GVF). The two entities are crowd-sourcing the funds and have pledged to make a free license available to developing countries who qualify for it.

The company's research is being conducted in conjunction with researchers at the University of Georgia's Center for Vaccines and Immunology.

Timeline

September 12, 2016
EpiVax raises a $600,000 grant from National Institutes of Health.
November 1, 2012
EpiVax raises a $55,000 grant from GBS/CIDP Foundation International.
September 5, 2012
EpiVax raises a $300,000 grant from National Institutes of Health.
April 9, 2012
EpiVax raises a $1,500,000 grant from National Institutes of Health.
January 25, 2011
EpiVax raises a $458,000 grant from National Institutes of Health.
November 26, 2008
EpiVax raises a $390,000 grant from National Institutes of Health.
July 8, 2008
EpiVax raises a $600,000 grant from National Institutes of Health.
February 28, 2007
EpiVax raises a $368,000 grant from National Institutes of Health.

Funding rounds

People

Name
Role
LinkedIn

Anne (Annie) S. De Groot, M.D.

CEO

Anthony G. Marcello

Employee

Chelsea Levesque

Employee

Clifford Grimm, MBA

CFO

Miriam Goldberg

Employee

Rebecca Martin

Employee

Sheila Chandran

Employee

William Martin

CIO

Further reading

Title
Author
Link
Type
Date

EpiVax Accelerates COVID-19 Vaccine Development with UGA's Center for Vaccines and Immunology

Web

March 4, 2020

EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countrie

Ulrich Martin

Web

Documentaries, videos and podcasts

Title
Date
Link

Executive Suite 10/11/2015: EpiVax CEO Annie De Groot

October 8, 2015

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
July 6, 2021
BioSpace
Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax - read this article along with other careers information, tips and advice on BioSpace
EpiVax Inc.
May 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. (« EpiVax ») annonce la publication de « Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for...
EpiVax Inc.
May 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. ("EpiVax") hat die Veröffentlichung der Studie "Hoch konservierte, nicht menschenähnliche und kreuzreaktive SARS-CoV-2...
EpiVax Inc.
May 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. ("EpiVax") anuncia la publicación "Epítopos de células T del SARS-CoV-2 altamente conservados, no similares a los humanos y con...
EpiVax Inc.
April 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. (« EpiVax ») annonce la publication « Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs » dans...
EpiVax Inc.
April 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. ("EpiVax") gibt die Veröffentlichung von "Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs" in...
BioSpace
April 27, 2021
BioSpace
EpiVax, Inc. ("EpiVax") announces the publication "Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs" in Frontiers in Immunology.
EpiVax Inc.
April 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. ("EpiVax") ha anunciado la publicación "Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs" in...
EpiVax Inc.
February 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. (« EpiVax ») annonce aujourd'hui sa participation au consortium INDIGO, un partenariat d'organismes de recherche et développement...
EpiVax Inc.
February 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. ("EpiVax") gibt heute seine Beteiligung am INDIGO-Konsortium bekannt - einer Partnerschaft öffentlicher und privater Forschungs-...
EpiVax Inc.
February 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. ("EpiVax") anuncia hoy su participación en el consorcio INDIGO, una asociación de organizaciones públicas y privadas de...
EpiVax Inc.
December 31, 2020
www.prnewswire.com:443
/PRNewswire/ -- EpiVax ("EpiVax") and EpiVax Therapeutics ("EVT") today provide an update on the advancement of their peptide-based COVID-19 vaccine,...
EpiVax Inc.
December 29, 2020
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. ("EpiVax") today provides an update on the advancement of the company's peptide therapeutic immunogenicity assessment program....
EpiVax, Inc.
December 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. annonce avoir battu tous les records cette année pour la trousse de dépistage de l'immunogénicité nommée « ISPRI ». Le nombre de...
EpiVax, Inc.
December 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. meldet ein rekordverdächtiges Jahr für das Immunogenitäts-Screening-Toolkit "ISPRI". Im Jahr 2020 unterzeichneten mehr Pharma- und...
EpiVax, Inc.
December 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. reporta un año récord para el conjunto de herramientas de detección de inmunogenicidad "ISPRI". Más empresas farmacéuticas y...
EpiVax, Inc.
December 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- EpiVax, Inc. reports a record-breaking year for the "ISPRI" immunogenicity screening toolkit. More pharmaceutical and biotechnology companies...
Bram Berkowitz
May 1, 2020
AmericanInno
It's time for another Ocean State Update.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.